Show simple item record

dc.contributor.authorNojiri, C
dc.contributor.authorKijima, T
dc.contributor.authorMaekawa, J
dc.contributor.authorHoriuchi, K
dc.contributor.authorKido, T
dc.contributor.authorSugiyama, T
dc.contributor.authorMori, T
dc.contributor.authorSugiura, N
dc.contributor.authorAsada, T
dc.contributor.authorUmemura, W
dc.contributor.authorOzaki, T
dc.contributor.authorSuzuki, M
dc.contributor.authorAkamatsu, T
dc.contributor.authorWestaby, S
dc.contributor.authorKatsumata, T
dc.contributor.authorSaito, S
dc.date.accessioned2019-09-19T11:53:59Z
dc.date.available2019-09-19T11:53:59Z
dc.date.issued2001-05-01T00:00:00Z
dc.identifier.issn0160-564X
dc.identifier.pmid11403674
dc.identifier.doi10.1046/j.1525-1594.2001.025005411.x
dc.identifier.urihttp://hdl.handle.net/2384/582905
dc.description.abstractWe have been developing an implantable left ventricular assist system (T‐ILVAS) featuring a magnetically suspended centrifugal pump (MSCP) since 1995. In vitro and in vivo studies using a prototype MSCP composed of a polycarbonate housing and impeller (196 ml) have demonstrated long‐term durability and excellent blood compatibility for up to 864 days, and excellent stability of the magnetic bearing of the MSCP. These preliminary results strongly suggested that the magnetic bearing of the MSCP is reliable and is a most feasible mechanism for a long‐term circulatory assist device. We have recently devised a clinical version pump made of titanium (180 ml) with a new position sensor mechanism and a wearable controller with batteries. Cadaver fit study confirmed that the Type IV pump could be implanted in a small patient with a body surface area as small as 1.3. The in vitro performance tests of the Type IV pump demonstrated excellent hydrodynamic performances with an acceptable hemolysis rate. New position sensors for the titanium housing showed more uniform sensor outputs of a magnetic bearing than in the prototype polycarbonate pump. The Type IV pump then was evaluated in vivo in 6 sheep at the Oxford Heart Centre. Four sheep were electively sacrificed at 3 months and were allowed to survive for more than 6 months for long‐term evaluation. In this particular series of experiments, no anticoagulant/antiplatelet regimen was utilized except for a bolus dose of heparin during surgery. There was a left ventricular mural thrombi around the inflow cannula in 1 sheep. Otherwise, there was no mechanical failure nor sign of thromboembolism throughout the study.en_US
dc.description.sponsorshipTerumoen_US
dc.titleDevelopment status of Terumo implantable left ventricular assist system.en_US
refterms.dateFOA2019-09-19T11:54:00Z
dc.source.journaltitleArtificial organsen_US


Files in this item

Thumbnail
Name:
nojiri2001.pdf
Size:
197.7Kb
Format:
PDF
Description:
Full text

This item appears in the following Collection(s)

Show simple item record